Back from BIO: The Evolving Biotech Investment Landscape
“Nuclear winter” and “extinction event” were two of the less-than-positive terms used during last month’s BIO International convention to describe the state of play for biotechs in recent years. Fortunately, while this may be only a partial exaggeration, there were many more positive notes as well. Fresh from my third BIO International and after digesting […]
Three Things we Learned in our World Preview 2025 Webinar
Every year, I am hugely fortunate to work with our team of experts to create the Evaluate World Preview report. Now in its 18th year, the World Preview offers a data-rich look at the future of the pharmaceutical industry. It’s full of forecast data that help to paint a picture of the shifting sands of […]
How can Pharma Navigate Turbulent Seas? Find out in our World Preview Webinar
The Evaluate World Preview report is a staple of the pharma calendar. The 2025 edition has just been published, marking the 18th year of providing forecast and trend insights to decision makers across the industry. If you’re not familiar with the World Preview, I recommend taking a look. Not only does it provide a wealth […]
Inside the Fundamentals of Forecasting: Highlights from Our Boston Workshop
Recently, the J+D Forecasting team welcomed a diverse group of professionals to Boston for our two-day Fundamentals of Forecasting multi-client workshop, run in collaboration with Evaluate. From emerging clinical-stage biotechs to global Top 10 pharma companies, delegates gathered to deepen their knowledge, share experiences, and engage in peer-to-peer learning in a relaxed, collaborative environment. The […]
Master patient flow analysis to predict pharma demand and provide better patient access.
Inaccurate patient flow analysis can create severe consequences even for the most diligent pharmaceutical companies. Risks include vastly overestimating or underestimating the value or opportunity for a particular product which may ultimately impact on patients’ ability to access potentially life-saving treatments. So, how can pharma companies minimize these risks and actively deliver products which support […]
Three Things we Learned in our Biotech Commercialization Webinar
The board at Verona Pharma was taking the steps necessary to take its chronic obstructive pulmonary disorder (COPD) drug to market years ahead of its launch in 2024. This long term view was one of the details shared by Verona’s Chief Commercial Officer, Chris Martin during our recent webinar “Going Solo: What’s Driving the Biotech […]
A Blueprint for Biotech Commercialization?
“Think twice, and twice more, before launching your own drug. It is unimaginably difficult and complex”. Those were the words of a biotech CEO I interviewed more than a decade ago. The advice remains sound. Yet today there are tailwinds encouraging more biotechs to take their prized assets all the way to market. (And let’s […]
Choosing the most Appropriate Time Series Algorithm for Accurate Pharmaceutical Sales Forecasts
When it comes to forecasting sales in the pharmaceutical industry, several time series algorithms are commonly used to analyze historical data and project trends into the future. These can be classified into three main types: Automated Smoothing First is the automated smoothing algorithm. This includes techniques such as growth rates and linear regression. Smoothing algorithms […]
Three Things we Learned in our “First to Market Myth” Webinar
It is a truth universally acknowledged that a new market in possession of unmet need will reward its first entrant with commercial advantage. Except, that “truth” may be somewhat overstated. This was the topic of our recent webinar, “The First to Market Myth: What Really Drives Launch Success?”. During the session, Evaluate consultants Mark Lansdell, […]
Should Pharma Companies Really Race to be First to Market?
For Portfolio Strategy teams in pharma companies, there is a constant juggling act to ensure that the right therapies are being prioritized for the right indications. This requires a clear understanding of the potential market size, payer perspectives and competitive environment. With the right data and insight, you can plan your go-to-market approach – and […]
